For example, one single-blinded study shows that a subcutaneous infusion of hormones including PYY, GLP-1, and oxyntomodulin (OXM) at a dose of 4/4/0.4 pmol/kg/min for 4 weeks significantly reduces body weight and improves glucose tolerance in patients with obesity and diabetes [112]. This evidence concerns the gene GCG and obesity disorder.